NANOLIGO
Financiado
Nanostar Sieving for Oligonucleotide Therapeutics
Since the Nobel Prize winning discovery of small interfering RNA its specificity and selectivity have driven the pharmaceutical industry to design 15- to 25-mer oligonucleotide analogues as a new class of drugs. These offer exciti...
Since the Nobel Prize winning discovery of small interfering RNA its specificity and selectivity have driven the pharmaceutical industry to design 15- to 25-mer oligonucleotide analogues as a new class of drugs. These offer exciting new therapeutic possibilities for example in rare diseases, but also large patient population indications including cardiovascular disease, and viral pandemics such as Covid-19. However, the high cost and limited scalability of manufacturing these complex polymeric molecules using solid phase synthesis is holding back benefits for thousands of patients – and has motivated us to seek an improved technology for oligo synthesis.
ERC Advanced Grant 786398 is funding research investigating a new technology platform for the fabrication of defined monomer sequence polymers - Nanostar Sieving. Our preliminary research into oligo synthesis using Nanostar Sieving has found that it is potentially both feasible and game-changing. NANOLIGO seeks proof-of-concept that Nanostar Sieving can unlock the tremendous potential of oligos through dramatically reducing production cost and increasing production capacity. We will work with RNA oligos – key targets for novel APIs – which are currently produced by solid phase synthesis, and show that these can be made entirely in the liquid phase, with unprecedentedly high purity, efficient chemistry and lower solvent consumption. Crucially, membrane separations are readily scaled up, making this process a strong candidate for kg-scale oligo production.
The PI and members of his research team have founded a start-up, Excatmer, to ensure the results of the ERC Grant have impact. We will carry out the PoC project at Exactmer, so that if we are successful the technology can be more rapidly developed and scaled up, leading to significant economic benefits. We are driven by a desire to make oligonucleotide therapies affordable and so available to patients as rapidly as possible.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2020-08-05
Fecha Fin: 2022-02-28
Fecha Fin: 2022-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-POC:
Call for proposals for ERC Proof of Concept Grant
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
EXACTMER LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
394.81K€ |
Participante